Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

A blood dendritic cell vaccine for acute myeloid leukemia expands anti-tumor T cell responses at remission.

Hsu JL, Bryant CE, Papadimitrious MS, Kong B, Gasiorowski RE, Orellana D, McGuire HM, Groth BFS, Joshua DE, Ho PJ, Larsen S, Iland HJ, Gibson J, Clark GJ, Fromm PD, Hart DN.

Oncoimmunology. 2018 Jan 25;7(4):e1419114. doi: 10.1080/2162402X.2017.1419114. eCollection 2018.

2.

A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.

van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, Koppes M, Kaspers J, Ossenkoppele GJ, Kruisbeek AM, de Gruijl TD.

Cancer Immunol Immunother. 2018 Oct;67(10):1505-1518. doi: 10.1007/s00262-018-2198-9. Epub 2018 Jul 23.

3.

The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.

Grabrucker C, Liepert A, Dreyig J, Kremser A, Kroell T, Freudenreich M, Schmid C, Schweiger C, Tischer J, Kolb HJ, Schmetzer H.

J Immunother. 2010 Jun;33(5):523-37. doi: 10.1097/CJI.0b013e3181d87ffd.

PMID:
20463595
4.
5.

Clinical trials of dendritic cell-based cancer vaccines in hematologic malignancies.

Pyzer AR, Avigan DE, Rosenblatt J.

Hum Vaccin Immunother. 2014;10(11):3125-31. doi: 10.4161/21645515.2014.982993. Review.

6.

Sequential modulation of growth factors: a novel strategy for adoptive immunotherapy of acute myeloid leukemia.

Zhong RK, Rassenti LZ, Kipps TJ, Chen J, Law P, Yu JF, Ball ED.

Biol Blood Marrow Transplant. 2002;8(10):557-68.

7.

CMRF-56(+) blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses.

Fromm PD, Papadimitrious MS, Hsu JL, Van Kooten Losio N, Verma ND, Lo TH, Silveira PA, Bryant CE, Turtle CJ, Prue RL, Vukovic P, Munster DJ, Nagasaki T, Barnard RT, Mahler SM, Anguille SA, Berneman Z, Horvath LG, Bradstock KF, Joshua DE, Clark GJ, Hart DN.

Oncoimmunology. 2016 May 5;5(6):e1168555. doi: 10.1080/2162402X.2016.1168555. eCollection 2016 Jun.

8.
9.

Impaired B cell immunity in acute myeloid leukemia patients after chemotherapy.

Goswami M, Prince G, Biancotto A, Moir S, Kardava L, Santich BH, Cheung F, Kotliarov Y, Chen J, Shi R, Zhou H, Golding H, Manischewitz J, King L, Kunz LM, Noonan K, Borrello IM, Smith BD, Hourigan CS.

J Transl Med. 2017 Jul 10;15(1):155. doi: 10.1186/s12967-017-1252-2.

10.
11.

Single step enrichment of blood dendritic cells by positive immunoselection.

López JA, Bioley G, Turtle CJ, Pinzón-Charry A, Ho CS, Vuckovic S, Crosbie G, Gilleece M, Jackson DC, Munster D, Hart DN.

J Immunol Methods. 2003 Mar 1;274(1-2):47-61.

PMID:
12609532
12.

Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia.

Rickmann M, Macke L, Sundarasetty BS, Stamer K, Figueiredo C, Blasczyk R, Heuser M, Krauter J, Ganser A, Stripecke R.

Ann Hematol. 2013 Aug;92(8):1079-90. doi: 10.1007/s00277-013-1744-y. Epub 2013 Apr 25.

13.

Dendritic cell vaccination in acute myeloid leukemia.

Anguille S, Willemen Y, Lion E, Smits EL, Berneman ZN.

Cytotherapy. 2012 Jul;14(6):647-56. doi: 10.3109/14653249.2012.693744. Review.

PMID:
22686130
14.

A systematic overview of chemotherapy effects in acute myeloid leukaemia.

Kimby E, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care.

Acta Oncol. 2001;40(2-3):231-52. Review.

PMID:
11441935
15.

Immunotherapy prospects for acute myeloid leukaemia.

Barrett AJ, Le Blanc K.

Clin Exp Immunol. 2010 Aug;161(2):223-32. doi: 10.1111/j.1365-2249.2010.04197.x. Epub 2010 May 31. Review.

16.

Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.

Talmadge JE.

Int Immunopharmacol. 2003 Aug;3(8):1121-43. Review.

PMID:
12860168
17.

New generation dendritic cell vaccine for immunotherapy of acute myeloid leukemia.

Subklewe M, Geiger C, Lichtenegger FS, Javorovic M, Kvalheim G, Schendel DJ, Bigalke I.

Cancer Immunol Immunother. 2014 Oct;63(10):1093-103. doi: 10.1007/s00262-014-1600-5. Epub 2014 Sep 4. Review.

PMID:
25186611
18.

Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses.

Choudhury BA, Liang JC, Thomas EK, Flores-Romo L, Xie QS, Agusala K, Sutaria S, Sinha I, Champlin RE, Claxton DF.

Blood. 1999 Feb 1;93(3):780-6.

19.

Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation.

Lee JJ, Kook H, Park MS, Nam JH, Choi BH, Song WH, Park KS, Lee IK, Chung IJ, Hwang TJ, Kim HJ.

J Clin Apher. 2004;19(2):66-70.

PMID:
15274198
20.

Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.

Liepert A, Grabrucker C, Kremser A, Dreyssig J, Ansprenger C, Freudenreich M, Kroell T, Reibke R, Tischer J, Schweiger C, Schmid C, Kolb HJ, Schmetzer H.

Cell Immunol. 2010;265(1):23-30. doi: 10.1016/j.cellimm.2010.06.009. Epub 2010 Jun 20.

PMID:
20663492

Supplemental Content

Support Center